Mamguem Kamga Ariane, Ouédraogo Samiratou, Kaboré Firmin Nongodo, Traoré Isidore Tiandiogo, Ouédraogo Esperance, Poda Armel, Diendéré Arnaud Eric, Kania Dramane, Badolo Hermann, Sanou Guillaume, Koné Amariane, Kagoné Therese Samdapawindé, Konaté Blahima, Médah Rachel, de Rekeneire Nathalie, Ouédraogo Boukary, Billa Oumar, Paradis Gilles, Tinto Halidou, Dabakuyo-Yonli Tienhan Sandrine
Centre Georges François Leclerc, Dijon, France.
National Population Health Observatory, National Institute of Public Health, Ouagadougou, Burkina Faso.
Front Public Health. 2025 Jul 10;13:1542024. doi: 10.3389/fpubh.2025.1542024. eCollection 2025.
To assess treatment and identify predictive factors of worsening in COVID-19 patients.
This study was ambispective (both prospective and retrospective) and part of a multidisciplinary, multicenter project designed to generate epidemiological, sociological and anthropological data about the COVID-19 epidemic in Burkina Faso. Medical records of patients admitted for COVID-19 at the hospitals of Ouagadougou and Bobo-Dioulasso from March 2020 to April 2021 were reviewed. To identify predictive factors of severe complications, we used Poisson regression models.
In total, 1,511 patients were included, of whom 70% were aged ≤50 years, 59% were men and 97% were living in an urban area. Of the 86% of patients treated, 92.9% of them received the combo Azithromycin-hydroxychloroquine. A total of 78 (5.2%) patients experienced complications during hospitalization, and 49 (3.3%) patients died. Multivariate analysis identified patient's age, residence and comorbidity as factors associated with poor outcomes.
Although most people had symptoms, most of them recovered without sequelae, and few patients had severe forms of disease. Age was a strong predictor of worse outcomes in this population.
评估2019冠状病毒病(COVID-19)患者的治疗情况并确定病情恶化的预测因素。
本研究为双向性研究(前瞻性和回顾性),是一个多学科、多中心项目的一部分,该项目旨在收集有关布基纳法索COVID-19疫情的流行病学、社会学和人类学数据。对2020年3月至2021年4月在瓦加杜古和博博迪乌拉索医院收治的COVID-19患者的病历进行了回顾。为了确定严重并发症的预测因素,我们使用了泊松回归模型。
共纳入1511例患者,其中70%年龄≤50岁,59%为男性,97%居住在城市地区。在接受治疗的86%的患者中,92.9%接受了阿奇霉素-羟氯喹组合治疗。共有78例(5.2%)患者在住院期间出现并发症,49例(3.3%)患者死亡。多变量分析确定患者的年龄、居住地和合并症是与不良预后相关的因素。
尽管大多数人有症状,但大多数人康复后无后遗症,少数患者病情严重。在这一人群中,年龄是预后较差的一个强有力的预测因素。